Lenalidomide Grindeks: Uses, Dosage & Side Effects
Immunomodulatory capsules for multiple myeloma and myelodysplastic syndromes
Lenalidomide Grindeks is a prescription immunomodulatory drug (IMiD) containing lenalidomide as its active substance. It is primarily used in the treatment of multiple myeloma and myelodysplastic syndromes (MDS). As a thalidomide analogue, lenalidomide carries a strict teratogenicity warning and requires adherence to a pregnancy prevention programme. This guide covers uses, dosage, side effects, interactions, and storage.
Quick Facts
Key Takeaways
- Lenalidomide Grindeks is an immunomodulatory drug used primarily for multiple myeloma and myelodysplastic syndromes with deletion 5q.
- It is strictly teratogenic — pregnancy must be excluded before starting treatment, and effective contraception is mandatory throughout treatment.
- Common side effects include neutropenia, thrombocytopenia, anaemia, and fatigue, requiring regular blood count monitoring.
- Lenalidomide increases the risk of venous thromboembolism, especially when combined with dexamethasone — prophylactic anticoagulation is often recommended.
- Always take this medicine exactly as prescribed by your haematologist or oncologist; never adjust the dose without medical advice.
What Is Lenalidomide Grindeks and What Is It Used For?
Lenalidomide Grindeks belongs to a class of medicines known as immunomodulatory drugs (IMiDs). The active substance, lenalidomide, is a potent analogue of thalidomide that was specifically developed to have enhanced anti-cancer and immune-modulating properties while reducing certain adverse effects associated with its parent compound. It was first approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) and has since become a cornerstone therapy in haematological oncology.
The mechanism of action of lenalidomide is multifaceted and involves several interconnected pathways. At the molecular level, lenalidomide binds to cereblon (CRBN), a substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex. This binding leads to the selective ubiquitination and subsequent proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for the survival and proliferation of myeloma cells. The degradation of these proteins leads to a cascade of anti-tumour effects, including direct cytotoxicity to malignant plasma cells.
Beyond its direct anti-neoplastic activity, lenalidomide exerts potent immunomodulatory effects. It enhances T-cell proliferation and the production of key cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ). Additionally, it augments the cytotoxic activity of natural killer (NK) cells, which play a crucial role in the immune surveillance of cancer cells. Lenalidomide also inhibits the production of pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), from monocytes.
The anti-angiogenic properties of lenalidomide are another important facet of its mechanism of action. By inhibiting the migration and adhesion of endothelial cells and reducing the levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), lenalidomide starves tumours of the blood supply they need to grow and spread. This multi-pronged approach — combining direct anti-tumour activity, immune enhancement, and anti-angiogenesis — accounts for the remarkable clinical efficacy of lenalidomide across multiple haematological malignancies.
Approved Indications
Lenalidomide Grindeks is authorised for use in the following conditions:
- Multiple myeloma (MM): As combination therapy with dexamethasone in adult patients who have received at least one prior therapy, as maintenance therapy after autologous stem cell transplantation (ASCT), or in combination with other agents for newly diagnosed patients not eligible for transplant.
- Myelodysplastic syndromes (MDS): For the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality, when other therapeutic options are insufficient or inadequate.
- Mantle cell lymphoma (MCL): As monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
- Follicular lymphoma (FL): In combination with rituximab for previously treated adult patients with follicular lymphoma (grade 1–3a).
What Should You Know Before Taking Lenalidomide Grindeks?
Before starting treatment with Lenalidomide Grindeks, your doctor will conduct a thorough evaluation of your medical history, current medications, and overall health status. It is essential that you understand the serious risks associated with this medicine and the precautions that must be followed throughout treatment. Lenalidomide is a strictly regulated medicine due to its teratogenic potential, and specific distribution programmes exist in most countries to ensure its safe use.
Contraindications
Lenalidomide is expected to cause severe birth defects if taken during pregnancy. It must not be used by pregnant women or women who may become pregnant unless all conditions of the pregnancy prevention programme are met. Even a single capsule taken during pregnancy can cause severe birth defects.
Lenalidomide Grindeks is contraindicated in the following situations:
- Pregnancy: Lenalidomide is teratogenic. It must not be used during pregnancy or by women of childbearing potential unless all conditions of the pregnancy prevention programme are fulfilled.
- Hypersensitivity: Patients with known hypersensitivity to lenalidomide or to any of the excipients listed in the product information.
- Women of childbearing potential who cannot or will not follow the required contraceptive measures as outlined in the pregnancy prevention programme.
Warnings and Precautions
Several important warnings and precautions must be considered when using lenalidomide:
- Haematological toxicity: Lenalidomide can cause significant neutropenia and thrombocytopenia. Complete blood counts must be monitored weekly during the first 8 weeks of therapy and at least monthly thereafter. Dose adjustments or treatment interruption may be necessary based on blood count results.
- Venous thromboembolism (VTE): An increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) has been reported, particularly when lenalidomide is combined with dexamethasone. Prophylactic anticoagulation or antiplatelet therapy should be considered based on individual patient risk factors.
- Second primary malignancies (SPM): An increase in second primary malignancies, including acute myeloid leukaemia (AML) and myelodysplastic syndromes, has been observed in myeloma patients receiving lenalidomide-based therapy. The benefit-risk balance should be carefully assessed before and during treatment.
- Hepatic disorders: Hepatic failure, including fatal cases, and elevated liver enzymes have been reported. Regular monitoring of liver function is recommended.
- Severe skin reactions: Serious cutaneous reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Treatment should be discontinued permanently if these reactions occur.
- Tumour lysis syndrome (TLS): Fatal cases of TLS have been reported. Patients at risk should be closely monitored and appropriate precautionary measures taken.
- Tumour flare reaction: May occur in patients with mantle cell lymphoma. Careful monitoring and management are recommended.
Pregnancy and Breastfeeding
The pregnancy prevention programme is a cornerstone of lenalidomide safety. Its key requirements include:
- Women of childbearing potential must use at least one effective method of contraception for at least 4 weeks before starting treatment, during treatment, during any dose interruptions, and for at least 4 weeks after the last dose. Pregnancy testing is required before, during, and after treatment.
- Male patients taking lenalidomide must use condoms during treatment and for at least 7 days after the last dose if their partner is pregnant or of childbearing potential. Male patients should not donate semen during treatment and for 7 days after discontinuation.
- Breastfeeding: It is not known whether lenalidomide is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding must be discontinued during treatment with lenalidomide.
- Fertility: Lenalidomide is present in semen at extremely low levels during treatment and is undetectable in semen 3 days after discontinuation in healthy subjects.
How Does Lenalidomide Grindeks Interact with Other Drugs?
Understanding potential drug interactions is critical for the safe and effective use of lenalidomide. While lenalidomide is not extensively metabolised by the cytochrome P450 enzyme system and is primarily excreted renally as unchanged drug, several clinically significant interactions have been identified. These interactions can affect the efficacy or safety profile of either lenalidomide or the co-administered medication.
Lenalidomide is not a substrate or inhibitor of major CYP450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5) or P-glycoprotein. However, its pharmacodynamic properties — including immunomodulation and effects on coagulation — can lead to meaningful interactions with certain drug classes. The combination of lenalidomide with dexamethasone, which is the standard treatment backbone for multiple myeloma, further amplifies some of these interaction risks.
Major Interactions
| Drug | Effect | Recommendation |
|---|---|---|
| Warfarin | Increased INR and prothrombin time; elevated bleeding risk | Monitor INR closely; adjust warfarin dose as needed |
| Erythropoietin (ESAs) | Increased risk of venous thromboembolism | Use with caution; consider thromboprophylaxis |
| Hormonal contraceptives | Potential reduced efficacy of oral contraceptives | Use additional non-hormonal contraception method |
| Dexamethasone (high-dose) | Increased VTE risk; enhanced immunosuppression | Mandatory thromboprophylaxis; monitor for infections |
Minor Interactions
| Drug | Effect | Recommendation |
|---|---|---|
| Digoxin | Increased digoxin plasma concentration (Cmax by 14%) | Monitor digoxin levels periodically |
| Statins | Potential increased risk of rhabdomyolysis with dexamethasone co-administration | Monitor for muscle symptoms; check CK levels if symptomatic |
| Antidiabetic agents | Dexamethasone co-therapy may impair glycaemic control | Monitor blood glucose closely; adjust diabetes medication |
Patients should always provide their treating physician with a complete list of all medications, including over-the-counter medicines, herbal supplements, and vitamins. This is particularly important because lenalidomide is often used in combination regimens, and the addition of multiple agents increases the complexity of potential interactions.
What Is the Correct Dosage of Lenalidomide Grindeks?
The dosage of Lenalidomide Grindeks is carefully tailored to the specific indication, the patient's renal function, and their tolerance of treatment. Lenalidomide capsules should be swallowed whole with water at approximately the same time each day. They should not be opened, broken, or chewed. If a patient handles a broken capsule, they should wash the affected skin area immediately with soap and water.
Adults
Multiple Myeloma — Newly Diagnosed (Not Transplant-Eligible)
Lenalidomide 25 mg once daily on days 1–21 of each 28-day cycle, in combination with dexamethasone 40 mg once daily on days 1, 8, 15, and 22 of each 28-day cycle. Treatment is continued until disease progression or unacceptable toxicity. For patients over 75 years, dexamethasone starting dose should be reduced to 20 mg once daily.
Multiple Myeloma — Maintenance After ASCT
Lenalidomide 10 mg once daily continuously on days 1–28 of each 28-day cycle. After 3 cycles, the dose may be increased to 15 mg once daily if tolerated. Treatment is continued until disease progression or unacceptable toxicity.
Myelodysplastic Syndromes (MDS) with Deletion 5q
Lenalidomide 10 mg once daily on days 1–21 of each 28-day cycle. Treatment should continue until disease progression, unacceptable toxicity, or for a minimum of 2–3 cycles to assess response.
Mantle Cell Lymphoma
Lenalidomide 25 mg once daily on days 1–21 of each 28-day cycle. Treatment is continued until disease progression or unacceptable toxicity.
Follicular Lymphoma
Lenalidomide 20 mg once daily on days 1–21 of each 28-day cycle (up to 12 cycles), in combination with rituximab. After 12 cycles, lenalidomide may continue as monotherapy on days 1–21 of each 28-day cycle until disease progression.
Children
Lenalidomide Grindeks is not indicated for use in children and adolescents under 18 years of age. There are no data from clinical trials in paediatric populations, and safety and efficacy have not been established in this age group. The medicine should not be administered to patients under 18 years.
Elderly
No specific dose adjustment is required based on age alone. However, elderly patients are more likely to have decreased renal function, and dose selection should be made with caution. The EMA recommends monitoring renal function in elderly patients. For patients aged 75 years and over receiving lenalidomide with dexamethasone for newly diagnosed multiple myeloma, the starting dose of dexamethasone should be reduced to 20 mg once daily on days 1, 8, 15, and 22. Elderly patients should also be monitored more closely for signs of thromboembolism, infection, and haematological toxicity.
Lenalidomide is primarily renally excreted. Dose adjustments are essential based on creatinine clearance (CrCl):
- CrCl 30–50 mL/min: 10 mg once daily (or 15 mg every 48 hours for 25 mg indication)
- CrCl < 30 mL/min (no dialysis): 7.5 mg once daily (or 5 mg once daily)
- CrCl < 30 mL/min (on dialysis): 5 mg once daily; on dialysis days, administer after dialysis
Missed Dose
If a dose of Lenalidomide Grindeks is missed and fewer than 12 hours have elapsed since the usual time, the patient should take the dose as soon as they remember. If more than 12 hours have passed, the patient should skip the missed dose and take the next dose at the usual scheduled time. Patients should never take a double dose to make up for a missed one. Patients should be advised to inform their healthcare provider if they miss a dose.
Overdose
There is limited experience with overdose of lenalidomide in clinical trials. In some dose-ranging studies, healthy volunteers received single doses up to 400 mg without serious adverse events. In the event of overdose, supportive care is recommended. Lenalidomide is partially dialysable; haemodialysis may be considered to remove lenalidomide from the bloodstream. There is no specific antidote for lenalidomide overdose. Patients who have taken more than the prescribed amount should contact their healthcare provider or local poison control centre immediately.
What Are the Side Effects of Lenalidomide Grindeks?
Like all medicines, Lenalidomide Grindeks can cause side effects, although not everybody gets them. Some side effects may be serious and require immediate medical attention. The frequency and severity of side effects can vary depending on the indication being treated, the dose used, and whether lenalidomide is given as monotherapy or in combination with other medicines.
The side effect profile of lenalidomide has been well characterised through extensive clinical trial data and post-marketing surveillance involving tens of thousands of patients worldwide. The most frequently reported adverse reactions across all indications are haematological in nature, reflecting the drug's mechanism of action on the bone marrow. It is crucial that patients undergoing lenalidomide treatment maintain regular follow-up appointments and blood tests as scheduled by their healthcare team.
Below is a comprehensive overview of side effects organised by frequency, using the standardised European classification system:
Very Common
Affects more than 1 in 10 patients
- Neutropenia (low neutrophil count)
- Thrombocytopenia (low platelet count)
- Anaemia (low red blood cell count)
- Leukopenia (low white blood cell count)
- Fatigue and asthenia
- Diarrhoea
- Constipation
- Nausea
- Muscle cramps and spasms
- Rash and pruritus
- Upper respiratory tract infections
- Peripheral oedema
- Pyrexia (fever)
- Insomnia
Common
Affects 1 to 10 in 100 patients
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Pneumonia and bronchitis
- Urinary tract infections
- Febrile neutropenia
- Elevated liver enzymes (ALT, AST)
- Hypokalaemia (low potassium)
- Renal failure
- Peripheral neuropathy
- Dizziness and headache
- Blurred vision
- Dry skin
- Abdominal pain
- Decreased appetite
Uncommon
Affects 1 to 10 in 1,000 patients
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Tumour lysis syndrome
- Tumour flare reaction
- Hepatic failure
- Interstitial lung disease
- Pancreatitis
- Angioedema
Rare
Affects fewer than 1 in 1,000 patients
- Second primary malignancies (AML, MDS, solid tumours)
- Severe hepatotoxicity
- Viral reactivation (hepatitis B)
- Progressive multifocal leukoencephalopathy (PML)
- Organ rejection in transplant recipients
- Anaphylaxis
Contact your doctor or seek emergency care immediately if you experience: sudden difficulty breathing or chest pain (possible pulmonary embolism), severe skin reactions with blistering or peeling, signs of severe infection (high fever, chills, severe sore throat), unusual bruising or bleeding, swelling or pain in one leg (possible DVT), or yellowing of the skin/eyes (possible liver failure).
How Should You Store Lenalidomide Grindeks?
Proper storage of Lenalidomide Grindeks is essential to maintain the integrity and efficacy of the medicine. Incorrect storage can lead to degradation of the active substance, potentially reducing therapeutic effectiveness or altering the safety profile. Given the teratogenic nature of lenalidomide, safe storage is also critical to prevent accidental exposure.
The following storage conditions should be observed at all times:
- Temperature: Store below 30°C. Do not refrigerate or freeze.
- Packaging: Keep the capsules in the original blister packaging to protect from moisture.
- Light: No special precautions regarding light exposure are required, though keeping capsules in original packaging is recommended.
- Children: Keep out of the sight and reach of children. This is especially important due to the teratogenic nature of the medicine.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month.
Unused or expired capsules should never be disposed of via household waste or wastewater. Due to the teratogenic risk, any unused medicine should be returned to a pharmacy for safe disposal in accordance with local requirements. This helps protect the environment and prevents accidental exposure.
What Does Lenalidomide Grindeks Contain?
Understanding the full composition of Lenalidomide Grindeks capsules is important for patients and healthcare professionals, particularly for those with known allergies or intolerances to specific excipients. The capsule composition varies slightly between strengths in terms of the capsule shell colourants, but the core formulation remains consistent.
Active Substance
The active substance in each capsule is lenalidomide. The available strengths are:
- 2.5 mg capsule: Each hard capsule contains 2.5 mg of lenalidomide
- 5 mg capsule: Each hard capsule contains 5 mg of lenalidomide
- 10 mg capsule: Each hard capsule contains 10 mg of lenalidomide
- 15 mg capsule: Each hard capsule contains 15 mg of lenalidomide
- 20 mg capsule: Each hard capsule contains 20 mg of lenalidomide
- 25 mg capsule: Each hard capsule contains 25 mg of lenalidomide
Inactive Ingredients (Excipients)
The capsule contents include the following inactive ingredients:
- Lactose monohydrate: Used as a filler/diluent. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
- Microcrystalline cellulose: Serves as a bulking agent and stabiliser.
- Croscarmellose sodium: Functions as a disintegrant to help the capsule contents dissolve properly.
- Magnesium stearate: Acts as a lubricant during the manufacturing process.
The capsule shell is composed of gelatin, titanium dioxide (E171), and various iron oxide colourants depending on the capsule strength. The different capsule colours help distinguish between strengths and reduce the risk of medication errors.
Frequently Asked Questions About Lenalidomide Grindeks
Medical References
This article is based on peer-reviewed medical literature and official prescribing information from regulatory agencies.
- European Medicines Agency (EMA) (2024). "Lenalidomide — Summary of Product Characteristics." EMA Product Information Official European prescribing information for lenalidomide.
- U.S. Food and Drug Administration (FDA) (2024). "Revlimid (lenalidomide) — Prescribing Information." FDA Label Full U.S. prescribing information including clinical trial data and safety information.
- National Comprehensive Cancer Network (NCCN) (2024). "NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma." NCCN Guidelines Comprehensive clinical guidelines for multiple myeloma treatment including lenalidomide-based regimens.
- Dimopoulos MA, et al. (2018). "Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma." New England Journal of Medicine. 357(21):2123-2132. Landmark phase 3 trial demonstrating efficacy of lenalidomide-dexamethasone in relapsed myeloma.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines — 23rd List." WHO Essential Medicines List Lenalidomide is included in the WHO Model List of Essential Medicines for cancer treatment.
- British National Formulary (BNF) (2024). "Lenalidomide — Indications, dose, interactions, and side-effects." BNF Monograph Concise clinical reference for prescribing information in the United Kingdom.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in oncology, haematology, clinical pharmacology, and internal medicine.